Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief People Officer | October 01, 2026 | October 03, 2026 |
| LiveRamp Holdings, Inc.ACXM · Entity 4412 | Chief People & Culture Officer | September 14, 2017 | September 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,900 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 2,659 · Balance 25,638 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 1,360 · Balance 26,998 Row 3 · 2026-10-01 · Tax withholding · Disposed 2,098 · Balance 24,900 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,637 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 2,659 · Balance 10,637 F2: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,162 |
Reported balance
After 2026-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-01 · Exercise / conversion · Disposed 1,360 · Balance 8,162 F4: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
LiveRamp Holdings, Inc.
Report date September 14, 2017 · Filed September 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.10 Par ValueSEC Table I · non-derivative | Direct | 62,146 |
Reported balance
After 2017-09-14 transaction · row 1
1 source rowRow 1 · 2017-09-14 · Tax withholding · Disposed 681 · Balance 62,146 F1: These shares were withheld by Acxiom Corporation to satisfy the reporting person's tax obligations that arose on September 14, 2017, when restricted stock units belonging to the reporting person vested. |
| Common Stock, $.10 Par ValueSEC Table I · non-derivative | Indirectby Managed Account 1 | 364.936 |
Reported balance
Holding disclosure · report date 2017-09-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 364.936 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by Acxiom Corporation to satisfy the reporting person's tax obligations that arose on September 14, 2017, when restricted stock units belonging to the reporting person vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000020 · wk-form4_1790974878.xml · derivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,162 Underlying: Common Stock · 1,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,659 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000020 · wk-form4_1790974878.xml · derivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,637 Underlying: Common Stock · 2,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,098 | $174.75 | $366,625.50 |
DisclosureSEC source: 0001652956-26-000020 · wk-form4_1790974878.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,900 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000020 · wk-form4_1790974878.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000020 · wk-form4_1790974878.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,012 | $0.00 Strike: $28.61 | $0.00 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · derivative · entry 9 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,615 Underlying: Common Stock · 14,012 shares Expires 2034-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,288 | $0.00 Strike: $20.14 | $0.00 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · derivative · entry 8 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,916 Underlying: Common Stock · 32,288 shares Expires 2034-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 400 | $167.92 | $67,167.52 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 7 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,979 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 13,248 | $166.11 | $2,200,584.21 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 6 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,379 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 19,014 | $165.16 | $3,140,310.41 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,627 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 9,934 | $164.27 | $1,631,870.10 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,641 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,704 | $163.41 | $605,285.83 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,575 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 14,012 | $28.61 | $400,883.32 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 32,288 | $20.14 | $650,280.32 |
DisclosureSEC source: 0001652956-26-000018 · wk-form4_1786663261.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,361 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000016 · wk-form4_1783030368.xml · derivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,522 Underlying: Common Stock · 1,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vests on April 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,659 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000016 · wk-form4_1783030368.xml · derivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,296 Underlying: Common Stock · 2,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,099 | $170.77 | $358,446.23 |
DisclosureSEC source: 0001652956-26-000016 · wk-form4_1783030368.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,979 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000016 · wk-form4_1783030368.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000016 · wk-form4_1783030368.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 21:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,832 | $92.68 | $355,149.76 |
DisclosureSEC source: 0001652956-26-000014 · wk-form4_1775598001.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,990 Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 5,359 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000012 · wk-form4_1775165016.xml · derivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,883 Underlying: Common Stock · 5,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,660 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000012 · wk-form4_1775165016.xml · derivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,955 Underlying: Common Stock · 2,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 4,187 | $91.15 | $381,645.05 |
DisclosureSEC source: 0001652956-26-000012 · wk-form4_1775165016.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,822 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 5,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000012 · wk-form4_1775165016.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000012 · wk-form4_1775165016.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:35 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 17,040 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000010 · wk-form4_1773448531.xml · derivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,040 Underlying: Common Stock · 17,040 shares Expires not disclosed F1 · derivative.exercise_date: This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,249 | $115.70 | $375,902.15 |
DisclosureSEC source: 0001652956-26-000008 · wk-form4_1769121927.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,990 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.345 to $116.150. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,619 | $113.48 | $410,681.59 |
DisclosureSEC source: 0001652956-26-000008 · wk-form4_1769121927.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,239 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.015 to $114.010. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,703 | $112.34 | $191,318.09 |
DisclosureSEC source: 0001652956-26-000008 · wk-form4_1769121927.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,858 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.77. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:39 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 17,379 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000006 · wk-form4_1768599558.xml · derivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,379 Underlying: Common Stock · 17,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on the one-year anniversary of January 15, 2024 and the remaining 67% of the shares vest annually over the remaining two-year period, thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:39 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 8,808 | $111.98 | $986,319.84 |
DisclosureSEC source: 0001652956-26-000006 · wk-form4_1768599558.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:39 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 17,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000006 · wk-form4_1768599558.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:09 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 88 | $113.44 | $9,982.69 |
DisclosureSEC source: 0001652956-26-000004 · wk-form4_1767992993.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,990 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.410 to $113.490. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:09 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,632 | $112.62 | $409,029.30 |
DisclosureSEC source: 0001652956-26-000004 · wk-form4_1767992993.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,078 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.260 to $113.250. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:09 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 6,311 | $111.75 | $705,267.50 |
DisclosureSEC source: 0001652956-26-000004 · wk-form4_1767992993.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,710 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.230 to $112.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,659 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000002 · wk-form4_1767654064.xml · derivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,615 Underlying: Common Stock · 2,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 14,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000002 · wk-form4_1767654064.xml · derivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,898 Underlying: Common Stock · 14,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 7,524 | $102.14 | $768,501.36 |
DisclosureSEC source: 0001652956-26-000002 · wk-form4_1767654064.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,021 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000002 · wk-form4_1767654064.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 14,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001652956-26-000002 · wk-form4_1767654064.xml · nonDerivative · entry 1 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $28.61 | $0.00 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · derivative · entry 11 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,627 Underlying: Common Stock · 15,000 shares Expires 2034-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025, and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $20.14 | $0.00 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · derivative · entry 10 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,204 Underlying: Common Stock · 35,000 shares Expires 2034-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This represents a stock option granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 800 | $107.03 | $85,624.00 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 9 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,920 F7 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.710 to $107.770. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 2,444 | $106.18 | $259,503.92 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 8 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,720 F6 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.680 to $106.670. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,923 | $105.33 | $202,549.59 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 7 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,164 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.680 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 664 | $107.85 | $71,612.40 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 6 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,087 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.730 to $107.970. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 6,786 | $106.90 | $725,423.40 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 5 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,751 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.625 to $107.560. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 23,974 | $106.15 | $2,544,840.10 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 4 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,537 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.625 to $106.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 18,576 | $105.33 | $1,956,610.08 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 3 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,511 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.625 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 15,000 | $28.61 | $429,150.00 |
DisclosureSEC source: 0001652956-25-000005 · wk-form4_1764815418.xml · nonDerivative · entry 2 Monroe Terilyn J. · CIK 0001652956 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.